# NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC

> **NCT06762158** · NA · ACTIVE_NOT_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **RADIATION:** Neoadjuvant Chemoradiotherapy
- **DRUG:** neoadjuvant immunotherapy
- **PROCEDURE:** Surgery
- **DRUG:** adjuvant immunotherapy

## Key facts

- **NCT ID:** NCT06762158
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2027-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762158, "NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06762158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*